Genflow Biosciences PLC
GENF
Company Profile
Business description
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.
Contact
6 Heddon Street
LondonW1B 4BT
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5
Stocks News & Analysis
stocks
Meta earnings: Early look at Muse adoption impresses investors
We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.
stocks
Tesla earnings: Shares fall on slower deliveries growth outlook; Raising valuation
Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,905.80 | 11.30 | -0.13% |
| CAC 40 | 7,779.46 | 31.80 | -0.41% |
| DAX 40 | 25,314.40 | 57.35 | -0.23% |
| Dow JONES (US) | 52,867.98 | 11.89 | 0.02% |
| FTSE 100 | 10,693.75 | 31.28 | -0.29% |
| HKSE | 23,093.37 | 158.69 | 0.69% |
| NASDAQ | 26,008.86 | 694.00 | -2.60% |
| Nikkei 225 | 62,693.16 | 214.68 | -0.34% |
| NZX 50 Index | 13,733.93 | 12.91 | -0.09% |
| S&P 500 | 7,663.43 | 93.74 | -1.21% |
| S&P/ASX 200 | 8,795.20 | 2.00 | 0.02% |
| SSE Composite Index | 3,690.48 | 32.45 | 0.89% |